Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
A somatostatin analog is a synthetic medicine designed to imitate actions of the natural hormone somatostatin. These drugs bind to one or more somatostatin receptor subtypes and suppress release of selected hormones and signaling molecules. They last longer in the body than natural somatostatin, which is broken down rapidly. Examples include octreotide, lanreotide, and pasireotide.
read more about somatostatin analog ...Somatostatin analogs are used to treat acromegaly and selected hormone-producing neuroendocrine tumors. Octreotide and lanreotide can reduce flushing and diarrhea associated with carcinoid syndrome and can control symptoms from certain other functional tumors. Some formulations can slow progression of selected gastroenteropancreatic neuroendocrine tumors. Pasireotide has approved uses for selected pituitary disorders, including Cushing disease or acromegaly, depending on the formulation.
Somatostatin receptors are G protein-coupled receptors found in the pituitary gland, gastrointestinal tract, pancreas, and many neuroendocrine tumors. Activating these receptors reduces secretion of growth hormone and several gastrointestinal or pancreatic hormones. The drugs can also reduce blood flow and secretory activity within the digestive system. Clinical effects differ because each analog has a distinct affinity for the five somatostatin receptor subtypes.
Products include short-acting subcutaneous injections, long-acting intramuscular injections, deep subcutaneous depot injections, and selected oral capsules. Long-acting formulations are administered at intervals that can extend for several weeks. Dosing is adjusted according to symptoms, hormone levels, tumor response, adverse effects, and product-specific instructions. Some patients receive a short-acting formulation before transition to a long-acting product.
Common effects include abdominal discomfort, nausea, diarrhea, constipation, injection-site reactions, and changes in blood glucose. Reduced gallbladder contraction can lead to gallstones or biliary complications during long-term treatment. Bradycardia, thyroid changes, vitamin B12 changes, liver-test abnormalities, and cardiac-conduction effects can occur with selected products. Monitoring can include glucose, gallbladder symptoms, thyroid function, heart rate, liver tests, hormone levels, and tumor assessment.
Yes. Octreotide is a synthetic somatostatin analog with longer activity than the natural hormone. It binds most strongly to selected somatostatin receptor subtypes.
They can control hormone-related symptoms and slow growth of selected somatostatin-receptor-positive neuroendocrine tumors. The benefit depends on tumor type, receptor expression, stage, and product.
Yes. They can reduce gallbladder contraction and bile flow, leading to gallstones or sludge during prolonged treatment. Many cases remain asymptomatic.
Yes. Suppression of insulin, glucagon, growth hormone, and other hormones can cause high or low blood glucose. Pasireotide is particularly associated with hyperglycemia.
Acromegaly. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK431086/. Date Accessed August 6, 2026.
Octreotide Acetate Injection: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f278f0d8-4062-420a-97c3-3a8b88253a08. Date Accessed August 6, 2026.
SOMATULINE DEPOT (Lanreotide Acetate Injection): Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e4a41fd-a753-4362-87ee-8cc56ed3660d. Date Accessed August 6, 2026.
SIGNIFOR LAR (Pasireotide for Injectable Suspension): Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0aad470-3f38-af97-e053-2995a90a383a. Date Accessed August 6, 2026.
Lanreotide. LiverTox (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK548368/. Date Accessed August 6, 2026.